USANA Health Sciences, Inc. $USNA Stock Position Reduced by Renaissance Technologies LLC

Renaissance Technologies LLC trimmed its position in USANA Health Sciences, Inc. (NYSE:USNA) by 11.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,017,630 shares of the company’s stock after selling 129,693 shares during the quarter. Renaissance Technologies LLC owned approximately 0.06% of USANA Health Sciences worth $17,778,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in USNA. UBS Group AG grew its position in shares of USANA Health Sciences by 252.3% in the 4th quarter. UBS Group AG now owns 138,334 shares of the company’s stock valued at $2,715,000 after buying an additional 99,063 shares during the last quarter. Vident Advisory LLC bought a new stake in USANA Health Sciences in the second quarter valued at approximately $437,000. Tidal Investments LLC increased its position in USANA Health Sciences by 45.9% during the 2nd quarter. Tidal Investments LLC now owns 16,906 shares of the company’s stock valued at $516,000 after purchasing an additional 5,318 shares during the period. Lazard Asset Management LLC raised its holdings in USANA Health Sciences by 130.3% during the 2nd quarter. Lazard Asset Management LLC now owns 23,201 shares of the company’s stock worth $708,000 after purchasing an additional 13,128 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of USANA Health Sciences by 969.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,243 shares of the company’s stock worth $282,000 after purchasing an additional 8,379 shares during the period. 54.25% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

USNA has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. Finally, Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

USANA Health Sciences Stock Performance

Shares of USANA Health Sciences stock opened at $22.16 on Friday. The stock has a market capitalization of $409.23 million, a PE ratio of 47.16, a price-to-earnings-growth ratio of 0.89 and a beta of 0.73. USANA Health Sciences, Inc. has a 52 week low of $16.60 and a 52 week high of $32.32. The stock has a 50 day moving average price of $20.38 and a two-hundred day moving average price of $19.74.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.17. USANA Health Sciences had a return on equity of 6.21% and a net margin of 0.96%.The company had revenue of $250.22 million for the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Research analysts forecast that USANA Health Sciences, Inc. will post 2.12 EPS for the current year.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, insider Brent Neidig sold 5,002 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $19.45, for a total transaction of $97,288.90. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director John Turman Fleming sold 2,450 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $17.93, for a total transaction of $43,928.50. Following the completion of the transaction, the director directly owned 4,230 shares in the company, valued at $75,843.90. This trade represents a 36.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 17,660 shares of company stock worth $336,579. Corporate insiders own 0.82% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.